个人中心 - 老虎社区

Jasonyoyoo

IP属地：未知

帖子 · 12帖子 · 12
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- JasonyoyooJasonyoyoo
  ·2021-07-13
  Good! Help like thanks
  非常抱歉，此主贴已删除
  1,690 1
  6
  分享
  举报
- JasonyoyooJasonyoyoo
  ·2021-07-11
  Best. Help like please
  Could The iPad Be Apple’s Best Performer in Fiscal Q3?<blockquote>iPad会成为苹果第三财季表现最好的产品吗？</blockquote>
  The Apple Maven believes that the iPad could be Apple’s best performer in fiscal Q3. Here is why. Th
  Could The iPad Be Apple’s Best Performer in Fiscal Q3?<blockquote>iPad会成为苹果第三财季表现最好的产品吗？</blockquote>
  1,212 1
  2
  分享
  举报
- JasonyoyooJasonyoyoo
  ·2021-07-07
  Like plz
  Mark Wahlberg-backed F45 targets over $1.5 bln valuation in U.S. IPO<blockquote>马克·沃尔伯格(Mark Wahlberg)支持的F45美国IPO估值目标超过15亿美元</blockquote>
  July 7 (Reuters) - Mark Wahlberg-backed fitness chain F45 Training Holdings Inc is eyeing a valuatio
  Mark Wahlberg-backed F45 targets over $1.5 bln valuation in U.S. IPO<blockquote>马克·沃尔伯格(Mark Wahlberg)支持的F45美国IPO估值目标超过15亿美元</blockquote>
  1,355 1
  2
  分享
  举报
- JasonyoyooJasonyoyoo
  ·2021-07-07
  Sad
  非常抱歉，此主贴已删除
  1,169 评论
  2
  分享
  举报
- JasonyoyooJasonyoyoo
  ·2021-06-30
  Like my comment please tq!
  非常抱歉，此主贴已删除
  1,477 1
  3
  分享
  举报
- JasonyoyooJasonyoyoo
  ·2021-06-30
  Very good
  These 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday<blockquote>这两家纳斯达克生物技术公司周二做出了令人瞠目结舌的举动</blockquote>
  The Nasdaq Composite(NASDAQINDEX:^IXIC)has done well recently, pushing to new record levels. The ind
  These 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday<blockquote>这两家纳斯达克生物技术公司周二做出了令人瞠目结舌的举动</blockquote>
  2,455 评论
  点赞
  分享
  举报
- JasonyoyooJasonyoyoo
  ·2021-06-27
  $Fastly, Inc.(FSLY)$gooooood
  1,503 1
  4
  分享
  举报
- JasonyoyooJasonyoyoo
  ·2021-06-20
  Yay
  非常抱歉，此主贴已删除
  1,263 评论
  1
  分享
  举报
- JasonyoyooJasonyoyoo
  ·2021-06-20
  Oh no
  非常抱歉，此主贴已删除
  1,242 评论
  点赞
  分享
  举报
- JasonyoyooJasonyoyoo
  ·2021-05-04
  😕
  非常抱歉，此主贴已删除
  1,524 评论
  3
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3577446101921159","uuid":"3577446101921159","gmtCreate":1614356511285,"gmtModify":1624169558813,"name":"Jasonyoyoo","pinyin":"jasonyoyoo","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/0f3ffe1c770fb88e35b82d572b5cdeb4","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":36,"tweetSize":12,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.07.18","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":145060204,"gmtCreate":1626183546908,"gmtModify":1633929319495,"author":{"id":"3577446101921159","authorId":"3577446101921159","name":"Jasonyoyoo","avatar":"https://static.tigerbbs.com/0f3ffe1c770fb88e35b82d572b5cdeb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577446101921159","idStr":"3577446101921159"},"themes":[],"htmlText":"Good! Help like thanks","listText":"Good! Help like thanks","text":"Good! Help like thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/145060204","repostId":"2151555866","repostType":4,"isVote":1,"tweetType":1,"viewCount":1690,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":148887563,"gmtCreate":1625967362452,"gmtModify":1633931326346,"author":{"id":"3577446101921159","authorId":"3577446101921159","name":"Jasonyoyoo","avatar":"https://static.tigerbbs.com/0f3ffe1c770fb88e35b82d572b5cdeb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577446101921159","idStr":"3577446101921159"},"themes":[],"htmlText":"Best. Help like please&nbsp;","listText":"Best. Help like please&nbsp;","text":"Best. Help like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/148887563","repostId":"1176789091","repostType":4,"repost":{"id":"1176789091","kind":"news","pubTimestamp":1625966668,"share":"https://www.laohu8.com/m/news/1176789091?lang=zh_CN&edition=full","pubTime":"2021-07-11 09:24","market":"us","language":"en","title":"Could The iPad Be Apple’s Best Performer in Fiscal Q3?<blockquote>iPad会成为苹果第三财季表现最好的产品吗？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1176789091","media":"TheStreet","summary":"The Apple Maven believes that the iPad could be Apple’s best performer in fiscal Q3. Here is why.\nTh","content":"<p>The Apple Maven believes that the iPad could be Apple’s best performer in fiscal Q3. Here is why.</p><p><blockquote>这位苹果专家认为，iPad可能是苹果第三财季表现最好的产品。原因如下。</blockquote></p><p> The Apple Maven continues its preview of the Cupertino company’s fiscal third quarter earnings day. So far, we have discussed (1)Wall Street’s expectationsfor revenues and earnings and (2) the expected performance of the iPhone in the quarter.</p><p><blockquote>苹果专家继续预览库比蒂诺公司第三财季财报日。到目前为止，我们已经讨论了(1)华尔街对收入和盈利的预期，以及(2)iPhone本季度的预期表现。</blockquote></p><p> Today, we address what could be Apple’s most successful product category in the third fiscal period of 2021: the iPad.</p><p><blockquote>今天，我们将讨论苹果在2021年第三财年最成功的产品类别：iPad。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/544b629337019373222b755bf493104b\" tg-width=\"1200\" tg-height=\"630\"><span>Figure 1: The latest iPad Pro model.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图1：最新的iPad Pro型号。</span></p></blockquote></p><p> The 2020 pandemic has made winners of tech companies that managed to capitalize on shifting consumer behavior – also known as the “stay at home” trends. This partially explains why iPad revenues have shot through the roof in the past several quarters: growth of at least 30% since fiscal Q2 last year.</p><p><blockquote>2020年的疫情让成功利用消费者行为转变（也称为“呆在家里”趋势）的科技公司成为赢家。这部分解释了为什么iPad收入在过去几个季度飙升：自去年第二财季以来增长了至少30%。</blockquote></p><p> For starters,it has become increasingly obviousthat consumers are not returning to old spending habits, even as the COVID-19 crisis gets closer to an end. Therefore, I see no reason to doubt that iPad sales will impress once again this time, although the growth rate will be partially eclipsed by tough 2020 comps.</p><p><blockquote>首先，越来越明显的是，即使新冠肺炎危机即将结束，消费者也不会恢复旧的消费习惯。因此，我认为没有理由怀疑iPad的销量这次将再次令人印象深刻，尽管增长率将被2020年的强劲业绩部分掩盖。</blockquote></p><p> But the story does not end with the effects of the pandemic. The chart below shows that, since around 2017, Apple has been able to reignite demand for its tablets. Even in 2019, before the pandemic turned the world upside down, iPad sales had already been growing at a respectable 13% pace.</p><p><blockquote>但故事并没有随着疫情的影响而结束。下图显示，自2017年左右以来，苹果已经能够重新点燃对其平板电脑的需求。即使在2019年，在疫情颠覆世界之前，iPad的销量也已经以13%的可观速度增长。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b463e314374d0f90f3cedbd13430a0ae\" tg-width=\"631\" tg-height=\"377\"><span>Figure 2: iPad revenue in millions U.S dollars.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图2：iPad营收百万美元。</span></p></blockquote></p><p> The rebirth of the tablet business, I will be frank,caught me by surprise. The phenomenon can be probably attributed to technological advancements allowing products like the iPad to better replace personal computers (more storage, better graphics, fast processor speed) and even smartphones (wider range of screen sizes, better cameras, introduction of 5G capability).</p><p><blockquote>坦率地说，平板电脑业务的重生让我大吃一惊。这种现象可能归因于技术进步，使iPad等产品能够更好地取代个人电脑（更大的存储空间、更好的图形、更快的处理器速度）甚至智能手机（更广泛的屏幕尺寸、更好的摄像头、5G功能的引入）。</blockquote></p><p> Case in point, Research and Marketsbelievesthat tablet revenues across the industry will continue to grow at a CAGR of over 10% through 2023. This is quite an improvement from the days that iPad sales were declining sharply, between 2014 and 2018.</p><p><blockquote>举个例子，Research and Markets认为，到2023年，整个行业的平板电脑收入将继续以超过10%的复合年增长率增长。与2014年至2018年间iPad销量急剧下降的日子相比，这是一个很大的进步。</blockquote></p><p> Lastly, Apple may have performed even better than its tablet competitors in the most recent quarter. First, the company has provenmore capable of managing its supply chain, which could be a plus during times of component shortages.</p><p><blockquote>最后，苹果最近一个季度的表现可能甚至比平板电脑竞争对手还要好。首先，该公司有能力管理其供应链，这在零部件短缺时期可能是一个优势。</blockquote></p><p> But also, Applereleased its new M1-equipped iPad Pro in April. Consumers have been more willing to pay up for better mobile devices lately, which might bode well for Apple’s top-of-the-line tablet. In fact, the iPad’s two percentage pointgainin market share in June could be explained by this product launch.</p><p><blockquote>而且，苹果在4月份发布了搭载M1的新款iPad Pro。消费者最近更愿意为更好的移动设备付费，这对苹果的顶级平板电脑来说可能是个好兆头。事实上，iPad 6月份市场份额增长了两个百分点可以用这次产品发布来解释。</blockquote></p><p> With the most recent tablet release, the entire iPad lineup (except for the less relevant mini version) is only about nine months old today. On the back of a strong product portfolio, the iPad could very well be the brightest star on Apple’s fiscal third quarter earnings day.</p><p><blockquote>随着最新平板电脑的发布，整个iPad系列（除了不太相关的迷你版本）今天只有大约九个月的历史。凭借强大的产品组合，iPad很可能成为苹果第三财季财报日最耀眼的明星。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Could The iPad Be Apple’s Best Performer in Fiscal Q3?<blockquote>iPad会成为苹果第三财季表现最好的产品吗？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCould The iPad Be Apple’s Best Performer in Fiscal Q3?<blockquote>iPad会成为苹果第三财季表现最好的产品吗？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">TheStreet</strong><span class=\"h-time small\">2021-07-11 09:24</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The Apple Maven believes that the iPad could be Apple’s best performer in fiscal Q3. Here is why.</p><p><blockquote>这位苹果专家认为，iPad可能是苹果第三财季表现最好的产品。原因如下。</blockquote></p><p> The Apple Maven continues its preview of the Cupertino company’s fiscal third quarter earnings day. So far, we have discussed (1)Wall Street’s expectationsfor revenues and earnings and (2) the expected performance of the iPhone in the quarter.</p><p><blockquote>苹果专家继续预览库比蒂诺公司第三财季财报日。到目前为止，我们已经讨论了(1)华尔街对收入和盈利的预期，以及(2)iPhone本季度的预期表现。</blockquote></p><p> Today, we address what could be Apple’s most successful product category in the third fiscal period of 2021: the iPad.</p><p><blockquote>今天，我们将讨论苹果在2021年第三财年最成功的产品类别：iPad。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/544b629337019373222b755bf493104b\" tg-width=\"1200\" tg-height=\"630\"><span>Figure 1: The latest iPad Pro model.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图1：最新的iPad Pro型号。</span></p></blockquote></p><p> The 2020 pandemic has made winners of tech companies that managed to capitalize on shifting consumer behavior – also known as the “stay at home” trends. This partially explains why iPad revenues have shot through the roof in the past several quarters: growth of at least 30% since fiscal Q2 last year.</p><p><blockquote>2020年的疫情让成功利用消费者行为转变（也称为“呆在家里”趋势）的科技公司成为赢家。这部分解释了为什么iPad收入在过去几个季度飙升：自去年第二财季以来增长了至少30%。</blockquote></p><p> For starters,it has become increasingly obviousthat consumers are not returning to old spending habits, even as the COVID-19 crisis gets closer to an end. Therefore, I see no reason to doubt that iPad sales will impress once again this time, although the growth rate will be partially eclipsed by tough 2020 comps.</p><p><blockquote>首先，越来越明显的是，即使新冠肺炎危机即将结束，消费者也不会恢复旧的消费习惯。因此，我认为没有理由怀疑iPad的销量这次将再次令人印象深刻，尽管增长率将被2020年的强劲业绩部分掩盖。</blockquote></p><p> But the story does not end with the effects of the pandemic. The chart below shows that, since around 2017, Apple has been able to reignite demand for its tablets. Even in 2019, before the pandemic turned the world upside down, iPad sales had already been growing at a respectable 13% pace.</p><p><blockquote>但故事并没有随着疫情的影响而结束。下图显示，自2017年左右以来，苹果已经能够重新点燃对其平板电脑的需求。即使在2019年，在疫情颠覆世界之前，iPad的销量也已经以13%的可观速度增长。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b463e314374d0f90f3cedbd13430a0ae\" tg-width=\"631\" tg-height=\"377\"><span>Figure 2: iPad revenue in millions U.S dollars.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图2：iPad营收百万美元。</span></p></blockquote></p><p> The rebirth of the tablet business, I will be frank,caught me by surprise. The phenomenon can be probably attributed to technological advancements allowing products like the iPad to better replace personal computers (more storage, better graphics, fast processor speed) and even smartphones (wider range of screen sizes, better cameras, introduction of 5G capability).</p><p><blockquote>坦率地说，平板电脑业务的重生让我大吃一惊。这种现象可能归因于技术进步，使iPad等产品能够更好地取代个人电脑（更大的存储空间、更好的图形、更快的处理器速度）甚至智能手机（更广泛的屏幕尺寸、更好的摄像头、5G功能的引入）。</blockquote></p><p> Case in point, Research and Marketsbelievesthat tablet revenues across the industry will continue to grow at a CAGR of over 10% through 2023. This is quite an improvement from the days that iPad sales were declining sharply, between 2014 and 2018.</p><p><blockquote>举个例子，Research and Markets认为，到2023年，整个行业的平板电脑收入将继续以超过10%的复合年增长率增长。与2014年至2018年间iPad销量急剧下降的日子相比，这是一个很大的进步。</blockquote></p><p> Lastly, Apple may have performed even better than its tablet competitors in the most recent quarter. First, the company has provenmore capable of managing its supply chain, which could be a plus during times of component shortages.</p><p><blockquote>最后，苹果最近一个季度的表现可能甚至比平板电脑竞争对手还要好。首先，该公司有能力管理其供应链，这在零部件短缺时期可能是一个优势。</blockquote></p><p> But also, Applereleased its new M1-equipped iPad Pro in April. Consumers have been more willing to pay up for better mobile devices lately, which might bode well for Apple’s top-of-the-line tablet. In fact, the iPad’s two percentage pointgainin market share in June could be explained by this product launch.</p><p><blockquote>而且，苹果在4月份发布了搭载M1的新款iPad Pro。消费者最近更愿意为更好的移动设备付费，这对苹果的顶级平板电脑来说可能是个好兆头。事实上，iPad 6月份市场份额增长了两个百分点可以用这次产品发布来解释。</blockquote></p><p> With the most recent tablet release, the entire iPad lineup (except for the less relevant mini version) is only about nine months old today. On the back of a strong product portfolio, the iPad could very well be the brightest star on Apple’s fiscal third quarter earnings day.</p><p><blockquote>随着最新平板电脑的发布，整个iPad系列（除了不太相关的迷你版本）今天只有大约九个月的历史。凭借强大的产品组合，iPad很可能成为苹果第三财季财报日最耀眼的明星。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.thestreet.com/apple/other-products/could-the-ipad-be-apples-best-performer-in-fiscal-q3\">TheStreet</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.thestreet.com/apple/other-products/could-the-ipad-be-apples-best-performer-in-fiscal-q3","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176789091","content_text":"The Apple Maven believes that the iPad could be Apple’s best performer in fiscal Q3. Here is why.\nThe Apple Maven continues its preview of the Cupertino company’s fiscal third quarter earnings day. So far, we have discussed (1)Wall Street’s expectationsfor revenues and earnings and (2) the expected performance of the iPhone in the quarter.\nToday, we address what could be Apple’s most successful product category in the third fiscal period of 2021: the iPad.\nFigure 1: The latest iPad Pro model.\nThe 2020 pandemic has made winners of tech companies that managed to capitalize on shifting consumer behavior – also known as the “stay at home” trends. This partially explains why iPad revenues have shot through the roof in the past several quarters: growth of at least 30% since fiscal Q2 last year.\nFor starters,it has become increasingly obviousthat consumers are not returning to old spending habits, even as the COVID-19 crisis gets closer to an end. Therefore, I see no reason to doubt that iPad sales will impress once again this time, although the growth rate will be partially eclipsed by tough 2020 comps.\nBut the story does not end with the effects of the pandemic. The chart below shows that, since around 2017, Apple has been able to reignite demand for its tablets. Even in 2019, before the pandemic turned the world upside down, iPad sales had already been growing at a respectable 13% pace.\nFigure 2: iPad revenue in millions U.S dollars.\nThe rebirth of the tablet business, I will be frank,caught me by surprise. The phenomenon can be probably attributed to technological advancements allowing products like the iPad to better replace personal computers (more storage, better graphics, fast processor speed) and even smartphones (wider range of screen sizes, better cameras, introduction of 5G capability).\nCase in point, Research and Marketsbelievesthat tablet revenues across the industry will continue to grow at a CAGR of over 10% through 2023. This is quite an improvement from the days that iPad sales were declining sharply, between 2014 and 2018.\nLastly, Apple may have performed even better than its tablet competitors in the most recent quarter. First, the company has provenmore capable of managing its supply chain, which could be a plus during times of component shortages.\nBut also, Applereleased its new M1-equipped iPad Pro in April. Consumers have been more willing to pay up for better mobile devices lately, which might bode well for Apple’s top-of-the-line tablet. In fact, the iPad’s two percentage pointgainin market share in June could be explained by this product launch.\nWith the most recent tablet release, the entire iPad lineup (except for the less relevant mini version) is only about nine months old today. On the back of a strong product portfolio, the iPad could very well be the brightest star on Apple’s fiscal third quarter earnings day.","news_type":1,"symbols_score_info":{"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":1212,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":140462531,"gmtCreate":1625669179523,"gmtModify":1633938507201,"author":{"id":"3577446101921159","authorId":"3577446101921159","name":"Jasonyoyoo","avatar":"https://static.tigerbbs.com/0f3ffe1c770fb88e35b82d572b5cdeb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577446101921159","idStr":"3577446101921159"},"themes":[],"htmlText":"Like plz","listText":"Like plz","text":"Like plz","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/140462531","repostId":"1170890468","repostType":4,"repost":{"id":"1170890468","kind":"news","pubTimestamp":1625666670,"share":"https://www.laohu8.com/m/news/1170890468?lang=zh_CN&edition=full","pubTime":"2021-07-07 22:04","market":"us","language":"en","title":"Mark Wahlberg-backed F45 targets over $1.5 bln valuation in U.S. IPO<blockquote>马克·沃尔伯格(Mark Wahlberg)支持的F45美国IPO估值目标超过15亿美元</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1170890468","media":"Reuters","summary":"July 7 (Reuters) - Mark Wahlberg-backed fitness chain F45 Training Holdings Inc is eyeing a valuatio","content":"<p>July 7 (Reuters) - Mark Wahlberg-backed fitness chain F45 Training Holdings Inc is eyeing a valuation of more than $1.5 billion in a U.S. initial public offering (IPO), months after terminating its merger with a blank-check company.</p><p><blockquote>路透7月7日-马克·沃尔伯格(Mark Wahlberg)支持的健身连锁店F45 Training Holdings Inc在终止与一家空白支票公司的合并几个月后，计划在美国首次公开募股(IPO)中估值超过15亿美元。</blockquote></p><p> The Austin, Texas-based company was founded in 2013 in Australia and now has more than 1,500 studios, with about 2,800 franchises in 63 countries.</p><p><blockquote>这家总部位于德克萨斯州奥斯汀的公司于2013年在澳大利亚成立，目前拥有1500多家工作室，在63个国家拥有约2800家特许经营店。</blockquote></p><p> F45 said on Wednesday it was aiming to sell about 20.3 million shares priced between $15 and $17 apiece to raise up to $345 million. About 1.6 million shares in the IPO are being offered by the selling stockholder, the proceeds of which would not go to the company.</p><p><blockquote>F45周三表示，计划以每股15美元至17美元的价格出售约2030万股股票，筹集至多3.45亿美元。出售股东将在IPO中发行约160万股股票，其收益不会归公司所有。</blockquote></p><p> F45 agreed in June last year to merge with Crescent Acquisition Corp, a special purpose acquisition company, but later canceled the deal as the COVID-19 pandemic shut several of its studios.</p><p><blockquote>F45去年6月同意与特殊目的收购公司Crescent Acquisition Corp合并，但后来由于COVID-19大流行关闭了其几家工作室而取消了交易。</blockquote></p><p> It posted an 11% drop in revenue for the year ended Dec. 31, 2020, with its net loss widening to $25.3 million from a loss of $12.6 million a year earlier.</p><p><blockquote>该公司公布截至2020年12月31日的财年收入下降11%，净亏损从上年同期的亏损1260万美元扩大至2530万美元。</blockquote></p><p> About 86% of the company's total studios were open as of March 31, according to its filing.</p><p><blockquote>根据其提交的文件，截至3月31日，该公司工作室总数中约有86%已开放。</blockquote></p><p> The company is seeking to list on the New York Stock Exchange and will trade under the ticker symbol \"FXLV.\"</p><p><blockquote>该公司正在寻求在纽约证券交易所上市，股票代码为“FXLV”。</blockquote></p><p> Goldman Sachs and J.P. Morgan are the lead underwriters for the offering.</p><p><blockquote>高盛和摩根大通是此次发行的主承销商。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mark Wahlberg-backed F45 targets over $1.5 bln valuation in U.S. IPO<blockquote>马克·沃尔伯格(Mark Wahlberg)支持的F45美国IPO估值目标超过15亿美元</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMark Wahlberg-backed F45 targets over $1.5 bln valuation in U.S. IPO<blockquote>马克·沃尔伯格(Mark Wahlberg)支持的F45美国IPO估值目标超过15亿美元</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-07-07 22:04</span>\n</p>\n</h4>\n</header>\n<article>\n<p>July 7 (Reuters) - Mark Wahlberg-backed fitness chain F45 Training Holdings Inc is eyeing a valuation of more than $1.5 billion in a U.S. initial public offering (IPO), months after terminating its merger with a blank-check company.</p><p><blockquote>路透7月7日-马克·沃尔伯格(Mark Wahlberg)支持的健身连锁店F45 Training Holdings Inc在终止与一家空白支票公司的合并几个月后，计划在美国首次公开募股(IPO)中估值超过15亿美元。</blockquote></p><p> The Austin, Texas-based company was founded in 2013 in Australia and now has more than 1,500 studios, with about 2,800 franchises in 63 countries.</p><p><blockquote>这家总部位于德克萨斯州奥斯汀的公司于2013年在澳大利亚成立，目前拥有1500多家工作室，在63个国家拥有约2800家特许经营店。</blockquote></p><p> F45 said on Wednesday it was aiming to sell about 20.3 million shares priced between $15 and $17 apiece to raise up to $345 million. About 1.6 million shares in the IPO are being offered by the selling stockholder, the proceeds of which would not go to the company.</p><p><blockquote>F45周三表示，计划以每股15美元至17美元的价格出售约2030万股股票，筹集至多3.45亿美元。出售股东将在IPO中发行约160万股股票，其收益不会归公司所有。</blockquote></p><p> F45 agreed in June last year to merge with Crescent Acquisition Corp, a special purpose acquisition company, but later canceled the deal as the COVID-19 pandemic shut several of its studios.</p><p><blockquote>F45去年6月同意与特殊目的收购公司Crescent Acquisition Corp合并，但后来由于COVID-19大流行关闭了其几家工作室而取消了交易。</blockquote></p><p> It posted an 11% drop in revenue for the year ended Dec. 31, 2020, with its net loss widening to $25.3 million from a loss of $12.6 million a year earlier.</p><p><blockquote>该公司公布截至2020年12月31日的财年收入下降11%，净亏损从上年同期的亏损1260万美元扩大至2530万美元。</blockquote></p><p> About 86% of the company's total studios were open as of March 31, according to its filing.</p><p><blockquote>根据其提交的文件，截至3月31日，该公司工作室总数中约有86%已开放。</blockquote></p><p> The company is seeking to list on the New York Stock Exchange and will trade under the ticker symbol \"FXLV.\"</p><p><blockquote>该公司正在寻求在纽约证券交易所上市，股票代码为“FXLV”。</blockquote></p><p> Goldman Sachs and J.P. Morgan are the lead underwriters for the offering.</p><p><blockquote>高盛和摩根大通是此次发行的主承销商。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/mark-wahlberg-backed-f45-targets-135813230.html\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index"},"source_url":"https://finance.yahoo.com/news/mark-wahlberg-backed-f45-targets-135813230.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1170890468","content_text":"July 7 (Reuters) - Mark Wahlberg-backed fitness chain F45 Training Holdings Inc is eyeing a valuation of more than $1.5 billion in a U.S. initial public offering (IPO), months after terminating its merger with a blank-check company.\nThe Austin, Texas-based company was founded in 2013 in Australia and now has more than 1,500 studios, with about 2,800 franchises in 63 countries.\nF45 said on Wednesday it was aiming to sell about 20.3 million shares priced between $15 and $17 apiece to raise up to $345 million. About 1.6 million shares in the IPO are being offered by the selling stockholder, the proceeds of which would not go to the company.\nF45 agreed in June last year to merge with Crescent Acquisition Corp, a special purpose acquisition company, but later canceled the deal as the COVID-19 pandemic shut several of its studios.\nIt posted an 11% drop in revenue for the year ended Dec. 31, 2020, with its net loss widening to $25.3 million from a loss of $12.6 million a year earlier.\nAbout 86% of the company's total studios were open as of March 31, according to its filing.\nThe company is seeking to list on the New York Stock Exchange and will trade under the ticker symbol \"FXLV.\"\nGoldman Sachs and J.P. Morgan are the lead underwriters for the offering.","news_type":1,"symbols_score_info":{".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":1355,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":140466163,"gmtCreate":1625669147052,"gmtModify":1633938507922,"author":{"id":"3577446101921159","authorId":"3577446101921159","name":"Jasonyoyoo","avatar":"https://static.tigerbbs.com/0f3ffe1c770fb88e35b82d572b5cdeb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577446101921159","idStr":"3577446101921159"},"themes":[],"htmlText":"Sad","listText":"Sad","text":"Sad","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/140466163","repostId":"1105988207","repostType":4,"isVote":1,"tweetType":1,"viewCount":1169,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":153504585,"gmtCreate":1625031414647,"gmtModify":1633945611388,"author":{"id":"3577446101921159","authorId":"3577446101921159","name":"Jasonyoyoo","avatar":"https://static.tigerbbs.com/0f3ffe1c770fb88e35b82d572b5cdeb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577446101921159","idStr":"3577446101921159"},"themes":[],"htmlText":"Like my comment please tq!&nbsp;","listText":"Like my comment please tq!&nbsp;","text":"Like my comment please tq!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/153504585","repostId":"1122418477","repostType":4,"isVote":1,"tweetType":1,"viewCount":1477,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":153504624,"gmtCreate":1625031390668,"gmtModify":1633945611510,"author":{"id":"3577446101921159","authorId":"3577446101921159","name":"Jasonyoyoo","avatar":"https://static.tigerbbs.com/0f3ffe1c770fb88e35b82d572b5cdeb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577446101921159","idStr":"3577446101921159"},"themes":[],"htmlText":"Very good&nbsp;","listText":"Very good&nbsp;","text":"Very good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/153504624","repostId":"1100317118","repostType":4,"repost":{"id":"1100317118","kind":"news","pubTimestamp":1625030487,"share":"https://www.laohu8.com/m/news/1100317118?lang=zh_CN&edition=full","pubTime":"2021-06-30 13:21","market":"us","language":"en","title":"These 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday<blockquote>这两家纳斯达克生物技术公司周二做出了令人瞠目结舌的举动</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1100317118","media":"Motley Fool","summary":"The Nasdaq Composite(NASDAQINDEX:^IXIC)has done well recently, pushing to new record levels. The ind","content":"<p>The&nbsp;<b>Nasdaq Composite</b>(NASDAQINDEX:^IXIC)has done well recently, pushing to new record levels. The index kept up its momentum on Tuesday, rising just over 0.1% as of 12:30 p.m. EDT.</p><p><blockquote>The<b>纳斯达克复合材料</b>（NASDAQINDEX：^IXIC）最近表现良好，创下历史新高。该指数周二保持势头，截至美国东部时间中午12:30上涨略高于0.1%。</blockquote></p><p> The Nasdaq is known for innovative companies, and a couple ofbiotech stocksgot a lot of attention on Tuesday.<b>Cerevel Therapeutics Holdings</b>(NASDAQ:CERE)got a nice push higher, but investors in&nbsp;<b>Sensei Biotherapeutics</b>(NASDAQ:SNSE)weren't as fortunate. Below, you'll get the details on both biotechs.</p><p><blockquote>纳斯达克以创新型公司而闻名，周二几只生物科技股受到了广泛关注。<b>Cerevel治疗控股公司</b>（纳斯达克：CERE）股价上涨，但投资者<b>唤醒生物治疗</b>（纳斯达克：SNSE）就没那么幸运了。下面，您将获得这两种生物技术的详细信息。</blockquote></p><p> Cerevel serves up an early win</p><p><blockquote>Cerevel早早获胜</blockquote></p><p> Shares of Cerevel were up 95% at middayon Tuesday after having more than doubled earlier in the session. The biotech company had good news from one of its key candidate treatments.</p><p><blockquote>Cerevel的股价在盘中早些时候上涨了一倍多后，周二中午上涨了95%。这家生物技术公司从其关键候选治疗方法之一传来了好消息。</blockquote></p><p> Cerevel announced positive results in its early-stage clinical trial of schizophrenia treatment CVL-231. The Cerevel treatment produced statistically significant improvements in a common scoring system for patients suffering from the disease compared to those who received a placebo. CVL-231 also produced encouraging safety and tolerability data that should be valuable in later-stage trials of the treatment.</p><p><blockquote>Cerevel宣布其治疗精神分裂症CVL-231的早期临床试验取得积极结果。与接受安慰剂的患者相比，Cerevel治疗在患有该疾病的患者的通用评分系统中产生了具有统计学意义的改善。CVL-231还产生了令人鼓舞的安全性和耐受性数据，这些数据在治疗的后期试验中应该是有价值的。</blockquote></p><p> The company was pleased with the results. Cerevel's chief scientific officer sees the results as supporting the broader idea that targeted therapy for certain muscarinic receptors could work as a viable treatment for schizophrenia. At the same time, the executive sees the potential to avoid major side effects of other types of treatments for the disease.</p><p><blockquote>该公司对结果感到满意。Cerevel的首席科学官认为，这些结果支持了更广泛的观点，即针对某些毒蕈碱受体的靶向治疗可以作为精神分裂症的可行治疗方法。与此同时，这位高管看到了避免该疾病其他类型治疗方法的主要副作用的潜力。</blockquote></p><p> Cerevel came public less than a year ago through a SPAC merger with Arya Sciences Acquisition. With the stock far above anywhere it has traded since then, Cerevel is now firmly on the radar for biotech investors across the market.</p><p><blockquote>不到一年前，Cerevel通过SPAC与Arya Sciences Acquisition合并上市。由于该股远高于此后的任何交易价格，Cerevel现在牢牢地受到了整个市场生物技术投资者的关注。</blockquote></p><p> A disappointment for Sensei</p><p><blockquote>老师的失望</blockquote></p><p> Shares of Sensei Biotherapeutics moved the other way, falling more than 15%. Investors weren't pleased to learn of the immunotherapy specialist's strategic reprioritization of its treatment pipeline.</p><p><blockquote>Sensei Biotherapeutics的股价则相反，下跌超过15%。投资者对这家免疫治疗专家对其治疗管道进行战略重新优先排序的消息并不高兴。</blockquote></p><p> Sensei made the decision to shift its priority to its current product candidates, which include the ImmunoPhage treatment SNS-401-NG and the monoclonal antibody SNS-VISTA. By doing so, it hopes to stretch its available cash to cover costs through the first half of 2024.</p><p><blockquote>Sensei决定将重点转移到当前的候选产品上，其中包括免疫噬菌体治疗SNS-401-NG和单克隆抗体SNS-VISTA。通过这样做，它希望扩大可用现金以支付2024年上半年的成本。</blockquote></p><p> Unfortunately, what that means is that Sensei will no longer continue its SNS-301 program. After analyzing clinical activity and data specific to the single-antigen treatment, Sensei believes that it has drawn as much insight as it can from its first-generation candidate. Further action from Sensei should come shortly, with SNS-VISTA studies coming by the end of this year and SNS-401-NG getting further attention in the second half of 2022.</p><p><blockquote>不幸的是，这意味着唤醒将不再继续其SNS-301计划。在分析了单抗原治疗的临床活动和特定数据后，Sensei相信它已经从第一代候选药物中获得了尽可能多的见解。唤醒的进一步行动应该很快就会到来，SNS-VISTA研究将于今年年底进行，SNS-401-NG将在2022年下半年得到进一步关注。</blockquote></p><p> Sensei just came public in early February through an IPO that generated considerable interest. Investors were excited by the hope of personalizing cancer medications to treat disease more effectively, and Sensei sold 7 million shares at $19 per share to IPO investors. First-day excitement sent the stock as high as $26.50 per share, but those gains proved short-lived, and the stock has moved steadily lower ever since. It now stands at less than half its IPO price.</p><p><blockquote>Sensei刚刚在2月初通过IPO上市，引起了相当大的兴趣。投资者对个性化癌症药物以更有效地治疗疾病的希望感到兴奋，Sensei以每股19美元的价格向IPO投资者出售了700万股股票。首日的兴奋使该股高达每股26.50美元，但事实证明这些涨幅是短暂的，此后该股稳步走低。现在它的价格还不到IPO价格的一半。</blockquote></p><p> The biotech industry is full of winners and losers, and it's a high-risk area that can produce huge gains when things go well and massive losses when they don't. Sensei's future seems more in doubt after today's news than it was before, but investors are taking a closer look at what Cerevel might have to offer over the long run.</p><p><blockquote>生物技术行业充满了赢家和输家，这是一个高风险领域，当事情进展顺利时会产生巨大的收益，当事情进展不顺利时会产生巨大的损失。今天的消息传出后，Sensei的未来似乎比以前更加令人怀疑，但投资者正在仔细研究Cerevel从长远来看可能提供的服务。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday<blockquote>这两家纳斯达克生物技术公司周二做出了令人瞠目结舌的举动</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday<blockquote>这两家纳斯达克生物技术公司周二做出了令人瞠目结舌的举动</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-06-30 13:21</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The&nbsp;<b>Nasdaq Composite</b>(NASDAQINDEX:^IXIC)has done well recently, pushing to new record levels. The index kept up its momentum on Tuesday, rising just over 0.1% as of 12:30 p.m. EDT.</p><p><blockquote>The<b>纳斯达克复合材料</b>（NASDAQINDEX：^IXIC）最近表现良好，创下历史新高。该指数周二保持势头，截至美国东部时间中午12:30上涨略高于0.1%。</blockquote></p><p> The Nasdaq is known for innovative companies, and a couple ofbiotech stocksgot a lot of attention on Tuesday.<b>Cerevel Therapeutics Holdings</b>(NASDAQ:CERE)got a nice push higher, but investors in&nbsp;<b>Sensei Biotherapeutics</b>(NASDAQ:SNSE)weren't as fortunate. Below, you'll get the details on both biotechs.</p><p><blockquote>纳斯达克以创新型公司而闻名，周二几只生物科技股受到了广泛关注。<b>Cerevel治疗控股公司</b>（纳斯达克：CERE）股价上涨，但投资者<b>唤醒生物治疗</b>（纳斯达克：SNSE）就没那么幸运了。下面，您将获得这两种生物技术的详细信息。</blockquote></p><p> Cerevel serves up an early win</p><p><blockquote>Cerevel早早获胜</blockquote></p><p> Shares of Cerevel were up 95% at middayon Tuesday after having more than doubled earlier in the session. The biotech company had good news from one of its key candidate treatments.</p><p><blockquote>Cerevel的股价在盘中早些时候上涨了一倍多后，周二中午上涨了95%。这家生物技术公司从其关键候选治疗方法之一传来了好消息。</blockquote></p><p> Cerevel announced positive results in its early-stage clinical trial of schizophrenia treatment CVL-231. The Cerevel treatment produced statistically significant improvements in a common scoring system for patients suffering from the disease compared to those who received a placebo. CVL-231 also produced encouraging safety and tolerability data that should be valuable in later-stage trials of the treatment.</p><p><blockquote>Cerevel宣布其治疗精神分裂症CVL-231的早期临床试验取得积极结果。与接受安慰剂的患者相比，Cerevel治疗在患有该疾病的患者的通用评分系统中产生了具有统计学意义的改善。CVL-231还产生了令人鼓舞的安全性和耐受性数据，这些数据在治疗的后期试验中应该是有价值的。</blockquote></p><p> The company was pleased with the results. Cerevel's chief scientific officer sees the results as supporting the broader idea that targeted therapy for certain muscarinic receptors could work as a viable treatment for schizophrenia. At the same time, the executive sees the potential to avoid major side effects of other types of treatments for the disease.</p><p><blockquote>该公司对结果感到满意。Cerevel的首席科学官认为，这些结果支持了更广泛的观点，即针对某些毒蕈碱受体的靶向治疗可以作为精神分裂症的可行治疗方法。与此同时，这位高管看到了避免该疾病其他类型治疗方法的主要副作用的潜力。</blockquote></p><p> Cerevel came public less than a year ago through a SPAC merger with Arya Sciences Acquisition. With the stock far above anywhere it has traded since then, Cerevel is now firmly on the radar for biotech investors across the market.</p><p><blockquote>不到一年前，Cerevel通过SPAC与Arya Sciences Acquisition合并上市。由于该股远高于此后的任何交易价格，Cerevel现在牢牢地受到了整个市场生物技术投资者的关注。</blockquote></p><p> A disappointment for Sensei</p><p><blockquote>老师的失望</blockquote></p><p> Shares of Sensei Biotherapeutics moved the other way, falling more than 15%. Investors weren't pleased to learn of the immunotherapy specialist's strategic reprioritization of its treatment pipeline.</p><p><blockquote>Sensei Biotherapeutics的股价则相反，下跌超过15%。投资者对这家免疫治疗专家对其治疗管道进行战略重新优先排序的消息并不高兴。</blockquote></p><p> Sensei made the decision to shift its priority to its current product candidates, which include the ImmunoPhage treatment SNS-401-NG and the monoclonal antibody SNS-VISTA. By doing so, it hopes to stretch its available cash to cover costs through the first half of 2024.</p><p><blockquote>Sensei决定将重点转移到当前的候选产品上，其中包括免疫噬菌体治疗SNS-401-NG和单克隆抗体SNS-VISTA。通过这样做，它希望扩大可用现金以支付2024年上半年的成本。</blockquote></p><p> Unfortunately, what that means is that Sensei will no longer continue its SNS-301 program. After analyzing clinical activity and data specific to the single-antigen treatment, Sensei believes that it has drawn as much insight as it can from its first-generation candidate. Further action from Sensei should come shortly, with SNS-VISTA studies coming by the end of this year and SNS-401-NG getting further attention in the second half of 2022.</p><p><blockquote>不幸的是，这意味着唤醒将不再继续其SNS-301计划。在分析了单抗原治疗的临床活动和特定数据后，Sensei相信它已经从第一代候选药物中获得了尽可能多的见解。唤醒的进一步行动应该很快就会到来，SNS-VISTA研究将于今年年底进行，SNS-401-NG将在2022年下半年得到进一步关注。</blockquote></p><p> Sensei just came public in early February through an IPO that generated considerable interest. Investors were excited by the hope of personalizing cancer medications to treat disease more effectively, and Sensei sold 7 million shares at $19 per share to IPO investors. First-day excitement sent the stock as high as $26.50 per share, but those gains proved short-lived, and the stock has moved steadily lower ever since. It now stands at less than half its IPO price.</p><p><blockquote>Sensei刚刚在2月初通过IPO上市，引起了相当大的兴趣。投资者对个性化癌症药物以更有效地治疗疾病的希望感到兴奋，Sensei以每股19美元的价格向IPO投资者出售了700万股股票。首日的兴奋使该股高达每股26.50美元，但事实证明这些涨幅是短暂的，此后该股稳步走低。现在它的价格还不到IPO价格的一半。</blockquote></p><p> The biotech industry is full of winners and losers, and it's a high-risk area that can produce huge gains when things go well and massive losses when they don't. Sensei's future seems more in doubt after today's news than it was before, but investors are taking a closer look at what Cerevel might have to offer over the long run.</p><p><blockquote>生物技术行业充满了赢家和输家，这是一个高风险领域，当事情进展顺利时会产生巨大的收益，当事情进展不顺利时会产生巨大的损失。今天的消息传出后，Sensei的未来似乎比以前更加令人怀疑，但投资者正在仔细研究Cerevel从长远来看可能提供的服务。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/06/29/these-2-nasdaq-biotechs-made-eye-popping-moves-tue/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CERE":"Cerevel Therapeutics Holdings, Inc.","SNSE":"Sensei Biotherapeutics, Inc."},"source_url":"https://www.fool.com/investing/2021/06/29/these-2-nasdaq-biotechs-made-eye-popping-moves-tue/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100317118","content_text":"The Nasdaq Composite(NASDAQINDEX:^IXIC)has done well recently, pushing to new record levels. The index kept up its momentum on Tuesday, rising just over 0.1% as of 12:30 p.m. EDT.\nThe Nasdaq is known for innovative companies, and a couple ofbiotech stocksgot a lot of attention on Tuesday.Cerevel Therapeutics Holdings(NASDAQ:CERE)got a nice push higher, but investors in Sensei Biotherapeutics(NASDAQ:SNSE)weren't as fortunate. Below, you'll get the details on both biotechs.\nCerevel serves up an early win\nShares of Cerevel were up 95% at middayon Tuesday after having more than doubled earlier in the session. The biotech company had good news from one of its key candidate treatments.\nCerevel announced positive results in its early-stage clinical trial of schizophrenia treatment CVL-231. The Cerevel treatment produced statistically significant improvements in a common scoring system for patients suffering from the disease compared to those who received a placebo. CVL-231 also produced encouraging safety and tolerability data that should be valuable in later-stage trials of the treatment.\nThe company was pleased with the results. Cerevel's chief scientific officer sees the results as supporting the broader idea that targeted therapy for certain muscarinic receptors could work as a viable treatment for schizophrenia. At the same time, the executive sees the potential to avoid major side effects of other types of treatments for the disease.\nCerevel came public less than a year ago through a SPAC merger with Arya Sciences Acquisition. With the stock far above anywhere it has traded since then, Cerevel is now firmly on the radar for biotech investors across the market.\nA disappointment for Sensei\nShares of Sensei Biotherapeutics moved the other way, falling more than 15%. Investors weren't pleased to learn of the immunotherapy specialist's strategic reprioritization of its treatment pipeline.\nSensei made the decision to shift its priority to its current product candidates, which include the ImmunoPhage treatment SNS-401-NG and the monoclonal antibody SNS-VISTA. By doing so, it hopes to stretch its available cash to cover costs through the first half of 2024.\nUnfortunately, what that means is that Sensei will no longer continue its SNS-301 program. After analyzing clinical activity and data specific to the single-antigen treatment, Sensei believes that it has drawn as much insight as it can from its first-generation candidate. Further action from Sensei should come shortly, with SNS-VISTA studies coming by the end of this year and SNS-401-NG getting further attention in the second half of 2022.\nSensei just came public in early February through an IPO that generated considerable interest. Investors were excited by the hope of personalizing cancer medications to treat disease more effectively, and Sensei sold 7 million shares at $19 per share to IPO investors. First-day excitement sent the stock as high as $26.50 per share, but those gains proved short-lived, and the stock has moved steadily lower ever since. It now stands at less than half its IPO price.\nThe biotech industry is full of winners and losers, and it's a high-risk area that can produce huge gains when things go well and massive losses when they don't. Sensei's future seems more in doubt after today's news than it was before, but investors are taking a closer look at what Cerevel might have to offer over the long run.","news_type":1,"symbols_score_info":{"SNSE":0.9,"CERE":0.9}},"isVote":1,"tweetType":1,"viewCount":2455,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":124213294,"gmtCreate":1624766543318,"gmtModify":1631885199145,"author":{"id":"3577446101921159","authorId":"3577446101921159","name":"Jasonyoyoo","avatar":"https://static.tigerbbs.com/0f3ffe1c770fb88e35b82d572b5cdeb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577446101921159","idStr":"3577446101921159"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FSLY\">$Fastly, Inc.(FSLY)$</a>gooooood","listText":"<a href=\"https://laohu8.com/S/FSLY\">$Fastly, Inc.(FSLY)$</a>gooooood","text":"$Fastly, Inc.(FSLY)$gooooood","images":[{"img":"https://static.tigerbbs.com/0dd4679d3514860a127ce0cc05ed1e49","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/124213294","isVote":1,"tweetType":1,"viewCount":1503,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":164052522,"gmtCreate":1624162408666,"gmtModify":1634009968310,"author":{"id":"3577446101921159","authorId":"3577446101921159","name":"Jasonyoyoo","avatar":"https://static.tigerbbs.com/0f3ffe1c770fb88e35b82d572b5cdeb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577446101921159","idStr":"3577446101921159"},"themes":[],"htmlText":"Yay","listText":"Yay","text":"Yay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/164052522","repostId":"1113942445","repostType":4,"isVote":1,"tweetType":1,"viewCount":1263,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164026119,"gmtCreate":1624162087931,"gmtModify":1634009979914,"author":{"id":"3577446101921159","authorId":"3577446101921159","name":"Jasonyoyoo","avatar":"https://static.tigerbbs.com/0f3ffe1c770fb88e35b82d572b5cdeb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577446101921159","idStr":"3577446101921159"},"themes":[],"htmlText":"Oh no","listText":"Oh no","text":"Oh no","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/164026119","repostId":"1126454279","repostType":4,"isVote":1,"tweetType":1,"viewCount":1242,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":106192454,"gmtCreate":1620091821478,"gmtModify":1634207894891,"author":{"id":"3577446101921159","authorId":"3577446101921159","name":"Jasonyoyoo","avatar":"https://static.tigerbbs.com/0f3ffe1c770fb88e35b82d572b5cdeb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577446101921159","idStr":"3577446101921159"},"themes":[],"htmlText":"😕","listText":"😕","text":"😕","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/106192454","repostId":"1147234999","repostType":4,"isVote":1,"tweetType":1,"viewCount":1524,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}